Chimeric Antigen Receptor Modified T Cells Infusion
Plasmacytoma
Shenzhen Geno-Immune Medical InstituteCell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Plasmacytoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE Memorial Sloan Kettering Cancer Center | Phase 2 | B |
Cediranib M.D. Anderson Cancer Center | Phase 2 | B |
cc-5013 Memorial Sloan Kettering Cancer Center | Phase 2 | B |
Pomalidomide Mayo Clinic | Phase 2 | B |
Busulphan M.D. Anderson Cancer Center | Phase 2 | B |
View all 19 →
Same molecule, other indications
Chimeric Antigen Receptor Modified T Cells Infusion is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →